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Cardiovascular complications are a major cause of morbidity
and mortality in patients with acromegaly. Normalization of
GH secretion is associatedwith an improvement in structural
and functional cardiac abnormalities.However, the long-term
cardiac effects of treatment for acromegaly have not been
studied in patients who have already developed chronic con-
gestive heart failure (CHF).
We reviewed the charts of 330 consecutive patients with
acromegaly treated in two French and Belgian centers since
1985. Ten patients with both acromegaly and CHF (eight men,
two women, mean age 49.7 yr) were studied retrospectively.
One of them was excluded because CHF was due to severe
aortic stenosis.
CHF (New York Heart Association stages III-IV and echo-
cardiography showing dilated hypokinetic cardiomyopathy
with left ventricular systolic dysfunction and a left ventric-
ular ejection fraction less than 45%) was diagnosed before,
concomitantly, or after acromegaly in, respectively, two, five,
and two patients. Three patients were referred with terminal
heart failure requiring transplantation.
One patient had transient CHF associated with a hyper-
tensive crisis. The other eight patients had symptomatic
chronic CHF. Control of GH hypersecretion failed, totally or
partially, in three patients: one had a long-term survival, and
the two others died at 1 and 5 yr. Good GH control was
achieved in five patients: four of these are still alive 2–16 yr
after diagnosis of CHF, their clinical status is stable or im-
proved, and their quality of life is good.Overall, the 1- and 5-yr
mortality (or transplantation) rates for patients with chronic
symptomatic CHF were 25% (2 of 8 patients) and 37.5% (3 of 8
patients), respectively.
In conclusion, less than 3% of acromegalic patients devel-
oped CHF in this study. Although effective treatment of ac-
romegaly improved short-term cardiovascular status, its im-
pact on long-term survival is questionable. (J Clin Endocrinol
Metab 89: 5308–5313, 2004)
CARDIOVASCULAR DISORDERS ARE the leadingcauses of morbidity and mortality in patients with
acromegaly (1, 2). GHhypersecretion appears to have adirect
detrimental effect on the heart, but other cardiovascular risks
factors such as hypertension and diabetes mellitus are often
associated (3, 4). Controlling GH hypersecretion can reverse
some features of acromegalic cardiomyopathy such as myo-
cardial hypertrophy and diastolic dysfunction (5, 6), partic-
ularly in patients younger than 45 yr (7), those with a short
history of GH hypersecretion (7), and those in whom GH
hypersecretion is controlled for more than 5 yr (8).
Diastolic dysfunction may lead to heart failure (9) in a
subgroup of patients. However, generally speaking, patients
with acromegaly complicated with heart failure have a con-
gestive dilated acromegalic cardiomyopathy with systolic
dysfunction. The vital prognosis for patients with congestive
heart failure (CHF) was poor until the late 1980s (death
within 1 yr), and treatment of acromegaly appeared ineffec-
tive (10). The advent of somatostatin analogs (SAs) led to a
marked improvement in cardiac function in some patients
with CHF, but follow-up was short (no more than 3 yr)
(11, 12).
The aim of this study was thus to determine the long-term
cardiac effects of acromegaly treatment in patientswithCHF.
Patients and Methods
Patients
We reviewed the charts of 330 consecutive patients with acromegaly
followed up in two centers (Department of Endocrinology, Biceˆtre Uni-
versity Hospital, le Kremlin-Biceˆtre, France, and Department of Endo-
crinology, Lie`ge University Hospital, Lie`ge, Belgium), 10 of whom had
CHF. One patient was excluded because CHF was due to severe aortic
stenosis.
Acromegaly was diagnosed on the basis of consensus criteria (13). All
nine patients had previously been treated for acromegaly (Table 1).
The diagnosis of CHF was based on clinical signs as described by the
Framingham Heart Study group (14) and the New York Heart Associ-
ation (NYHA) classification (for stages III and IV) and echocardiography
showing a left ventricular ejection fraction (LVEF) of 45% or less (15–17).
Some data concerning short-term evolution have been previously
reported (11, 12).
Methods
Detailed histories were obtained for each patient. Information on the
treatment of acromegaly and its efficacy, other complications of acro-
megaly, long-term outcome, and the dates and causes of death was
collected. Good control of acromegaly was defined by IGF-I normal-
ization, a GH level less than 2 g/liter, and suppression of GH by oral
Abbreviations: CHF, Congestive heart failure; EF, ejection fraction;
LV, left ventricular; LVEF, LV ejection fraction; NYHA, NewYorkHeart
Association; SA, somatostatin analog.
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glucose tolerance test (18). GHand IGF-1Iwere assayedwith commercial
kits (19).
Because it was difficult to know the precise date of onset of acro-
megaly, we used the duration of uncontrolled GH between diagnosis
and successful treatment.
Other diseases and cardiovascular risk factors were carefully re-
viewed. With regard to the cardiac history, changes in cardiac status on
treatment and the results of serial echocardiographic measurements
were analyzed. M-mode, two-dimensional, and pulsed Doppler echo-
cardiographic studies were performedwith commercial ultrasound sys-
tems, using a 2.5-MHz transducer during three to five consecutive car-
diac cycles. The following measurements were recorded on M-mode
trace (20): left ventricular (LV) end-diastolic diameter, end-systolic di-
ameter, interventricular septum thickness, LV posterior wall thickness,
LVEF, and fractional shortening. Cardiac catheterization and coronary
angiography were performed in seven patients. Serial LVEF measure-
ments (Table 2) were made by echocardiography.
Results
Characteristics of the patients at diagnosis of acromegaly
and congestive heart failure
Nine patients (Table 1) among the 330 consecutive patients
with acromegaly (2.7%) met the clinical and echocardio-
graphic criteria for systolic heart failure (Table 2). CHF was
diagnosed 1 and 10 yr before, concomitantly, and 11 and 14
yr after diagnosis of acromegaly in two, five and two pa-
tients, respectively.
At diagnosis of CHF, the NYHA classification was stages
IV and III in seven and two patients, respectively. Basal
echocardiographic findings in the nine patients are summa-
rized in Table 2. Three patients (no. 5, 6, and 7) were referred
for heart transplantation.
One patient (no. 9) had all the characteristics of CHF at
presentation, but the immediate outcome suggested that la-
tent asymptomatic LV dysfunction had been triggered by a
hypertensive crisis. The other eight patients all had chronic
CHF.
Basal echocardiography showed dilation of the LV, except
in patient 9. Myocardial hypertrophy was present in four of
the five patients for whom the relevant information was
available. The LVEF was decreased in all the patients (mean
28.1%; range 11–45%) (Table 2). Diastolic parameters were
not available at baseline. Systolic dysfunction with low car-
diac output was confirmed by right ventricular catheteriza-
tion in seven patients (data not shown). Individual risks
factors for cardiac disease and relevant comorbidities are
detailed in Table 2.
No relationwas found between severity of LV dysfunction
[evaluated in terms of ejection fraction (EF)] and the time
since CHF onset.
Cardiac outcome
Patient with precipitated heart failure. The patient whose heart
failure was precipitated by a hypertensive crisis is still alive
after 9 yr of follow-up. His EF (70%) remained stable.
Patients with chronic symptomatic CHF
Course of heart failure and LVEF. Follow-up ranged between
1 and 16 yr (mean 6 yr) in the eight patients with symptom-
atic CHF and systolic dysfunction. Two of them (no. 3 and
5) developed reversible atrial arrhythmias. They received
maximal treatment for CHF (Table 2). LVEF improved sig-
nificantly (20% increase) in three patients, deteriorated sig-
nificantly in two patients, and remained stable in the other
three patients (Fig. 1). In patient 2, EF was initially 11% and
increased to 45% after heart transplantation. No improve-
ment in LV, diastolic diameters, or myocardial hypertrophy
was observed by echocardiography during follow-up.
Short-term outcome
Cardiac outcome was poor during the first year of follow-
up in two patients: one died suddenly (no. 8), and another
required transplantation 4 months after the diagnosis (pa-
tient 2). This latter patient is still alive after 14 yr of follow-up.
Thus, the mortality (or heart transplantation) rate at 1 yr was
25%. In the other six patients, treatment of acromegaly and
heart failure markedly improved cardiac status, correcting
congestive signs within a few months. Three and two pa-
tients reached NYHA stages II and III, respectively. Two
patients (no. 1 and 7) returned to work (reaching NYHA
stage I) and one patient (no. 1) tolerated a substantial re-
duction in cardiac pharmacotherapy (digitalis withdrawal
and reduction in the diuretic dose).
TABLE 1. Biochemical levels at the time of diagnosis and at the last visit during follow-up in nine patients with acromegaly and CHF
Patient no. Sex/age (yr) atdiagnosis of acromegaly
Basal hormonal levels Treatments of
acromegalya
Time with good control of
GH/IGF hypersecretion (yr)
Hormonal levels at the
last visit during follow-up
GH IGF-I GH IGF-I
1 M/34 60 900b S, SA 3 0.8 350b
2 M/41 3.2 960b S, RT 6 0.1 280
3 M/43 6.5 690b S, RT, SA 12 0.8 210
4 M/63 12 680b SA 2 4.5 220
5 M/59 264 NA SA Partial control 31 370b
6 M/38 11 NA SA Partial control 3 260
7 F/59 6.9 670b S 5 3 180
8 M/47 39 550b S, SA No control 45 510b
9 M/62 10.2 330b S, SA 8 0.1 111
Upper limit of normal range for IGF-I according to age: 410 g/liter (30–40 yr), 375 (40–50), 315 (50–60), 285 (60–70), 265 (70–80), 155
(80).
aS, Surgery; SA, somatostatin analogs; RT, radiotherapy.
bSupranormal levels of IGF-I; NA, not available.
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Long-term outcome
At the last evaluation, five of the eight patients with CHF
had died (n 4) or undergone heart transplantation (n 1).
All the deaths were of cardiac origin (Table 2). The 5-yr
mortality (or transplantation) rate was 37.5%.
Control of GH/IGF-I secretion and cardiac outcome (Fig. 2
and Table 1)
Control of GH hypersecretion was only partial in three
patients: two had a poor cardiac outcome (no. 5 and 8); they
died after 1 and 5 yr of follow-up, respectively. In the last
patient (no. 6), referred 10 yr after the diagnosis of CHF,
cardiac status improved markedly during the first 4 yr of SA
therapy but then deteriorated, and he died of refractory CHF
14 yr after diagnosis of CHF. Strict control of GH hyperse-
cretionwith SAwas achieved only during the last year of this
patient’s life.
Good control of acromegaly was achieved in five patients
(no. 1, 2, 3, 4, and 7). IGF-I normalizationwas obtained in four
patients (no. 1, 2, 4, 7) within the first months of SA therapy
in three of them. In the fifth patient (no. 3), IGF-I normalized
after 4 yr, thanks to radiotherapy and SA therapy. One of
these five patients died after 6 yr of follow-up (patient 7).
Patient 2 underwent heart transplantation and is still alive.
The other patients are still alive.
Myocardial histology
Cardiac specimens were available in two cases. The ex-
planted heart of the patient who was transplanted (no. 2)
showed only endothelial fibrosis of coronary arteries; no
intramyocardial fibrosis was found. The histological char-
acteristics of the other patient, who had a cardiac biopsy
before and 1 yr after effective treatment of acromegaly (no.
7), have been described in detail elsewhere (12): the first
biopsy showed major myofibrillolysis and interfascicular fi-
brosis, both of which improved significantly after 1 yr of






































































































































































































































































































































































































































































































































































































































































































































































































































































































FIG. 1. Course of LVEF in patients with acromegaly and CHF. Val-
ues at baseline (at the time of diagnosis of CHF) and at the last
determination during follow-up are presented. Black and open sym-
bols indicate good and bad control of GH/IGF-I hypersecretion, re-
spectively. In patient 2 the last EF value (45%) was obtained after
heart transplantation.
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Discussion
Prevalence
Only 3% of patients with acromegaly in this series devel-
oped severe CHF. This figure is lower than generally re-
ported (10, 21, 22), but these older studies were performed
at a time when the treatment of acromegaly (and its co-
morbidities) was less aggressive and when CHF was diag-
nosed on the basis of less modern criteria and/or without
the use of echocardiography. In addition, the treatment and
follow-up of patients with acromegaly have improvedmark-
edly during the last two decades, and the risk of CHF is
probably lower than before.
Pathophysiology
This small population of acromegalic patients with CHF
was not very different from the general population of pa-
tients with acromegaly. Importantly, most of our patients
had hypertension (eight of nine), although blood pressure
controlwas good inmost cases. Three of the nine patients had
diabetes, a prevalence similar to that observed in the global
population of acromegalic patients (4, 23, 24). The duration
of uncontrolled acromegaly in our series was also similar to
that observed in the general population of acromegalic pa-
tients (23, 24).
We found no specific risk factors for developing CHF in
patients who were likely to have a previous common un-
complicated hypertrophic acromegalic cardiomyopathy.
The natural history of CHF in acromegaly is largely un-
known (25). In the rat, chronic GH hypersecretion increases
myocardial performance, improving cardiomyocyte contrac-
tility and reducing energy costs (26). However, cardiac hy-
pertrophy and fibrosis eventually occur (3). We are aware of
only one natural animal model of cardiomyopathy, repro-
ducing the classical progression from acromegalic hypertro-
phic cardiomyopathy to ventricular dilation and systolic
impairment (27). In humans, the duration of myocardial
hypertrophy or ventricular dilation before CHF onset is
unknown.
Prognosis of CHF
We chose to analyze separately the patient with transient
CHF associated with an acute episode of hypertension, in
whom LV function improved rapidly after resolution of the
precipitating factor. Such factors can reveal asymptomatic
LV dysfunction. Rapid recovery of LV function is associated
with good long-term outcome (28).
The global prognosis of acromegalic patients with chronic
CHF remains poor. In our series, themortality/transplantation
rate was 25% at 1 yr and 37.5% at 5 yr. These rates are very
similar to those seen in patients with other causes of systolic
heart failure (17, 29, 30) and suggest that the treatment of ac-
romegaly fails to improve the long-term prognosis when ac-
romegalic cardiomyopathy with LV systolic dysfunction is al-
FIG. 2. Individual long-term outcome
in nine patients with acromegaly and
CHF, according to time and control of
GH/IGF-I hypersecretion. Time at di-
agnosis of acromegaly is indicated by a
triangle; time at diagnosis of CHF is
indicated by a closed circle. Plain line
indicates good control and dotted line
indicates bad control of GH/IGF-I hy-
persecretion. Arrows indicate that the
patients are still alive, whereas death
or heart transplantation is indicated by
a vertical line.
FIG. 3. Histological view of the heart obtained at myocardial biopsy
in a patient with CHF before treatment and after cure of acromegaly.
Before treatment (left) an extensive intracellularmyofibrillolysiswith
areas of myocytolysis and cellular infiltrate is observed. After the
effective treatment of acromegaly (right), biopsy shows major regres-
sion of the disorders. [Courtesy of Albert Beckers, CD-ROM, Pituitary
adenomas, 2003, Albert Beckers and GraphMed, Lie`ge, Belgium.]
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ready present, confirming reports from McGuffin et al. (2) and
Hayward et al. (10) a few years ago. Recently, Damjanovic et al.
(9) reported similar, poor outcome among patients with early
heart failure, but the criteriaused todefineCHFwerenot clearly
defined in this paper. All our patients received near-maximal
cardiologic treatment concomitantly with treatment for acro-
megaly, and it is therefore difficult to determine the prognostic
impact of each treatment. Interestingly, the cardiac prognosis
seemed to be similar whether or not treatment for acromegaly
was effective: two of the five patients whose acromegaly was
well controlledbymedical therapyand twoof the threepatients
with poor control had a poor outcome.
Cardiac hypertrophy anddilationmay be irreversible once
CHF occurs: treatment that lowers GH levels does not seem
to improve cardiac structural abnormalities, contrary towhat
is observed in earlier stages of the disease (31–34),when good
GHcontrol can lead to regression of cardiac hypertrophy and
improve both diastolic function (33–35) and exercise toler-
ance (increase in the exercise-induced EF increment) (36, 37).
Thus, at an advanced stage of cardiomyopathy, fibrosis,
arrhythmias, and valve abnormalities may be irreversible.
Lie (38) was the first to observe these abnormalities, in au-
topsy studies of acromegalic patients. This irreversibility
could be due to chronic exposure to high GH/IGF-I levels,
whereas lymphocyte infiltration could be reduced by treat-
ment (12). One of our patients showed an improvement in
myocardial histology (decreased myofibrillolysis and inter-
fascicular fibrosis) during SA therapy.
Heart disease is generally considered to be the leading
cause of mortality among acromegalic patients (1, 24). Two
sudden deaths occurred in our series, one in a patient known
to have ventricular arrhythmia. The prevalence of arrhyth-
mias is probably underestimated in acromegaly (39); they
can be corrected when GH hypersecretion is controlled (40,
41). Because CHF seems to be rare, most cardiac deaths
would appear to be due to arrhythmias; 24-h electrocardio-
graphic recordingwas recently recommended in a consensus
statement on acromegalic complications (42).
Although the long-term prognosis of CHF remains poor in
patients with acromegaly, some patients show an immediate
improvement in clinical status and an increase in the LVEF
when treatment for acromegaly is started, possibly owing to
the marked reduction in extracellular volume when GH hy-
persecretion is controlled (review in Ref. 43). Diuretic treat-
ment may thus have a synergistic beneficial impact on car-
diac status. Specific treatment of chronic heart failure may
also help to improve cardiac function. Angiotensin-convert-
ing enzyme inhibitors and -blockers are used to limit car-
diac remodeling (44), and they have proved to be effective in
reducing mortality and morbidity in patients with heart fail-
ure of various causes (45–47). Whether treatment of acro-
megaly has an impact on myocardial contractile function at
this stage of the disease is presently unknown.
Intensive management of these patients with severe car-
diac disease (regular visits, dietary advice, verification of
treatment adherence, treatment of comorbidities, etc.) no
doubt contributes to improving vital outcome. Correction of
arrhythmias (which may precipitate heart failure) may be
sufficient to improve the ejection fraction (48).
In conclusion, CHF is a rare complication of acromegaly,
occurring in less than 3% of patients. The vital prognosis is
variable.When an acute episode such as a hypertensive crisis
or arrhythmia precipitates transient CHF, with rapid recov-
ery of myocardial dysfunction, initial cardiac status is gen-
erally recovered and is maintained by effective management
of acromegaly. In contrast, patients with CHF, chronic di-
lated cardiomyopathy, and LV systolic dysfunction have a
poor prognosis, similar to that of patients with CHF of other
causes. Indeed, the mortality (or transplantation) rates in our
series were 25% at 1 yr and 37.5% at 5 yr. Treatment of
acromegaly seems to improve cardiac function in the short
term but probably has little or no effect on myocardial hy-
pertrophy, ventricular dilation, or the long-term prognosis.
This indicates that myocardial damage is irreversible at this
stage of acromegalic cardiomyopathy. These patients there-
fore need optimal therapy for heart failure and effective
prevention of sudden death due to cardiac arrhythmia.
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